BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Acquired by Royal Bank of Canada

Royal Bank of Canada increased its holdings in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 3.5% in the first quarter, Holdings Channel.com reports. The firm owned 70,391 shares of the company’s stock after purchasing an additional 2,399 shares during the period. Royal Bank of Canada’s holdings in BeOne Medicines were worth $20,905,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new position in BeOne Medicines during the second quarter worth about $67,657,000. Man Group plc purchased a new stake in BeOne Medicines in the 2nd quarter valued at about $59,031,000. BNP Paribas Financial Markets acquired a new position in shares of BeOne Medicines during the 2nd quarter valued at about $38,337,000. First Trust Advisors LP increased its stake in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of BeOne Medicines during the 2nd quarter worth about $26,034,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ONC. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Friday, July 17th. Citizens Jmp reaffirmed a “market outperform” rating and set a $396.00 price target on shares of BeOne Medicines in a research note on Wednesday, July 1st. Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. JPMorgan Chase & Co. upped their price objective on BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Finally, Nomura raised BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines currently has an average rating of “Moderate Buy” and an average price target of $394.00.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
• Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
• Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
• Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing

Insider Activity

In other news, CEO John Oyler sold 145,861 shares of the stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total value of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares in the company, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the sale, the chief operating officer owned 40 shares in the company, valued at approximately $10,774.80. The trade was a 97.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 345,561 shares of company stock worth $105,625,947 over the last three months. 6.19% of the stock is currently owned by corporate insiders.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $327.53 on Thursday. The firm has a fifty day moving average of $294.53 and a 200-day moving average of $308.67. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $35.94 billion, a P/E ratio of 73.27 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.